Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Fri7,674.37+0.43%

Nasdaq · Fri26,180.46+0.43%

Dow · Fri53,277.01+0.98%

Russell 2000 · Fri3,017.87+0.85%

VIX · Fri15.13low, stale to cash close

U.S. futures · 08:23ES −0.24%NQ −0.78% · YM −0.09%

U.S. 2Y / 10Y4.227% / 4.704%−0.7 / −3.4 bp

Dollar index98.871+0.07%

WTI Oct / Gold Dec$85.31 / $4,705−2.01% / +0.53%

Nikkei / Hang Seng65,568 / 25,504−0.68% / −1.94%

Shanghai / KOSPI3,872 / 6,698−0.85% / −3.10%

Europe · Fri closeSXXP 654.18Euro Stoxx 50 6,462 · DAX 26,137 · FTSE 10,817

1 · Risk tone

Tech leads futures lower

September Nasdaq-100 futures underperform S&P and Dow futures before Europe opens. That is a negative opening indication—not a cash-session forecast—especially with NVIDIA reporting Wednesday. CNBC NQ futures

2 · Macro

Gold firm despite cheaper oil

Gold +0.53% and DXY +0.07% coexist with WTI −2.01%; this mix fits haven/policy uncertainty more than a simple inflation trade. U.S. 10Y yields are 3.4 bp lower overnight but remain elevated at 4.704%. gold · 10Y

3 · Event

Wednesday is a two-stage repricing

BEA releases Q2 GDP second estimate and July income/outlays at 08:30 ET; NVIDIA reports after the close. Rates first, AI expectations second. BEA · NVIDIA IR

Market drivers

Macro, central banks and geopolitics

Asia confirms caution: KOSPI −3.10%, Hang Seng −1.94%, Shanghai −0.85% and Nikkei −0.68%; Australia bucked the move at +0.49%. CNBC world markets
Iran sanctions remain the headline channel: current reports say markets await details of new U.S. sanctions; WTI's drop argues against treating the headline as an immediate supply shock, while gold remains firm. live news feed
Data concentration: official BEA schedule confirms both GDP and income/outlays on Aug. 26 at 08:30 ET. No FOMC meeting occurs this week; the next scheduled meeting is Sep. 15–16. BEA · Fed
Trade risk: the prior report's U.S.–Canada tariff escalation remains an opening-gap variable; policy details and sector breadth—not headline direction alone—must confirm impact. CNBC

Earnings, regulation and rotation

NVIDIA Wednesday: Nasdaq's earnings calendar lists NVDA after hours with an EPS consensus of $2.01 from 11 estimates; consensus is vendor-supplied, not guidance. CRWD, CRM and SNPS also appear after hours. Nasdaq calendar
Primary filing check: SEC submissions show NVIDIA's latest filing as an Aug. 17 8-K; IonQ's latest quarterly filing was an Aug. 10 10-Q, accompanied that week by prospectus/registration filings. Filing existence does not establish direction. NVDA SEC · IONQ SEC
Friday correction matters: direct Nasdaq closes show NVDA +0.99% and VRT +1.02%, while AVGO −1.20%, ANET −2.60% and AMD −0.80% versus Thursday. The previous report mistakenly labeled CNBC's Aug. 20 single-stock observations as Friday data; those claims and derived levels are withdrawn. Nasdaq NVDA summary
Rates versus growth: lower overnight yields cushion duration, but 4.704% on the 10Y and event risk make any pre-open relief fragile. CNBC/Tradeweb

Theme dashboards

AI · selective

Event risk overwhelms clean trend signals

Verified Friday: NVDA $216.85 (+0.99% from Thursday) and VRT $264.63 (+1.02%); ANET $183.75 (−2.60%), AVGO $364.03 (−1.20%) and AMD $469.455 (−0.80%). Nasdaq
Catalyst: NVIDIA Wednesday can reprice compute, networking, memory, cloud, power and cooling expectations. Nasdaq lists NVDA, CRM and SNPS the same evening. calendar
Risk: high expectations, 4.7% long yields, export controls, customer concentration, power availability and demand elasticity. Reported system-price increases remain secondary reporting, not company guidance. CNBC

Quantum · avoid chase

Friday reversed Thursday's surge

Verified Friday reversals: RGTI −10.30%, QUBT −8.74%, QBTS −7.80% and IONQ −7.42% versus Thursday closes. Nasdaq Friday market caps were approximately $6.0B, $2.0B, $7.5B and $17.1B respectively. IONQ quote
Primary check: IonQ filed its 10-Q Aug. 10; D-Wave's Aug. 18 8-K discussed a DOCOMO deployment, but disclosed deployment headlines do not by themselves prove durable unit economics. IONQ filings · QBTS 8-K
Risk: small/high-beta names face dilution, commercialization, architecture, valuation and squeeze risk. No borrow availability or fee is implied.

Peptide biotech

Pipeline evidence, valuation separation

Retatrutide: ClinicalTrials.gov lists the 1,152-participant Phase 3 T2D/obesity study NCT05929079 completed; Lilly previously announced pivotal Phase 3 obesity results, but registry completion alone proves neither efficacy nor safety. registry · Lilly
Market Friday: LLY −0.88%, NVO −1.28%, while small-cap VKTX +1.39% to $34.36. Nasdaq VKTX
Risk: efficacy must be weighed against GI/safety profile, discontinuations, manufacturing, reimbursement and regulatory path. VKTX carries trial and financing/binary exposure; it is not a penny or OTC stock.

Ranked ideas — conditional; fewer is better

1Conditional bullish

VRT · Vertiv (NYSE)

Risk class: large/mid-cap high-beta AI power/cooling · Classification: confirmation-only long · Horizons: day trade after opening range; 1–4 week swing only after NVIDIA; 3–12+ months selectively on fundamentals. Direction uncertain.

Thesis/catalyst: Friday's $264.63 close was +1.02% while several AI peers fell. NVIDIA results can validate data-center deployment velocity and power/cooling demand.

Evidence / counterargument: relative strength and profitable infrastructure exposure support it. Counter: Nasdaq futures weakness, high valuation/duration, project timing, supply execution and a binary read-through Wednesday.

Entry/confirmation: hold $260 and reclaim Friday's $268.20 high with semiconductor breadth. Invalidation/downside: close below Friday's $257.49 low; downside reference $250. Avoid carrying oversized event exposure. Nasdaq data

Thesis Confidence 69

Risk 82

Opportunity 64

2Speculative watch-to-long

VKTX · Viking Therapeutics (Nasdaq)

Risk class: small-cap clinical biotech; binary/dilution sensitive · Classification: conditional momentum long, not core investment · Horizons: day/swing only; 3–12+ months requires trial/regulatory de-risking. Direction uncertain.

Thesis/catalyst: $34.36 Friday (+1.39%) showed relative strength against LLY/NVO. Oral/injectable obesity-program updates offer optionality.

Evidence / counterargument: theme demand and Friday strength help. Counter: no new pivotal evidence verified this morning; cash burn, trial safety/efficacy, manufacturing, competition and financing dominate.

Entry/confirmation: reclaim Friday's $34.98 high on volume. Invalidation/downside: close below $33.47; next reference $30. Binary gaps can exceed stops. Not penny/OTC. Nasdaq data

Thesis Confidence 55

Risk 91

Opportunity 56

1Avoid pre-event chase

NVDA · NVIDIA (Nasdaq)

Risk class: mega-cap, high-duration / earnings-gap · Classification: avoid fresh swing before results; tactical bearish only on confirmation · Horizons: day trade; 1–4 weeks after earnings; 3–12+ month thesis valuation-dependent.

Thesis/catalyst: Friday rebounded to $216.85, but NQ futures are −0.78% and Wednesday combines macro data with earnings. Reward for adding unhedged event exposure is poor.

Evidence / counterargument: concentration and gap risk support avoidance. Counter: pricing power, profitable scale and a strong guide can gap the stock upward.

Entry/confirmation: no pre-event swing entry; tactical bearish only below $214 with weak semis, and do not carry it through earnings. Invalidation/downside: reclaim $220; bearish references $210/$200. Short loss is unlimited; no borrow claim. Nasdaq

Thesis Confidence 78

Risk 94

Opportunity 50

2Avoid / no active short

RGTI / QUBT / QBTS / IONQ · quantum basket

Risk class: small/high-beta speculative growth; squeeze/dilution prone · Classification: avoid chase, not a borrow recommendation · Horizons: day trade only; 1–4 week observation; no 3–12+ month entry absent stronger commercial economics.

Thesis/catalyst: Friday erased 7%–10% after Thursday's surge, exposing unstable momentum and weak valuation anchors.

Evidence / counterargument: Nasdaq closes verify the reversal; SEC filings confirm financing/registration activity at IonQ. Counter: government demand and deployments can produce violent rallies and real option value.

Entry/confirmation: no blind short; bearish only after failed rebounds and breaks below Friday closes: RGTI $16.07, QUBT $8.14, QBTS $18.80, IONQ $41.53. Invalidation: sustained reclaim of Thursday closes. Short losses unlimited; availability/fees unknown. SEC

Thesis Confidence 72

Risk 96

Opportunity 45

No third bullish or bearish idea: pre-event asymmetry and corrected single-stock data do not support forcing another call.

Watchlist — maximum five

Ticker / risk class	Classification & horizon	Thesis / catalyst / counterargument	Confirmation / invalidation / key risks	C / R / O
Watch AVGO Nasdaq · large-cap AI/custom silicon	Repair watch. Day: opening range. Swing: post-NVDA. Long term: after Sep. 2 expected earnings.	$364.03 Friday, −1.20%; NVIDIA and Broadcom results can validate networking/custom silicon. Counter: relative weakness, rates and customer concentration.	Reclaim $368; invalidate below $360 then $350. Integration, leverage, capex and event-gap risk.	65 / 81 / 61
Watch ANET NYSE · liquid AI networking growth	Repair only. Day/swing after reclaim; 3–12 months only with valuation/FCF support.	Friday −2.60% to $183.75 corrected the prior false leadership read. NVIDIA is read-through. Counter: profitable growth and demand can reassert.	Reclaim $188.65; invalidate below $180. Customer concentration, valuation, competition.	67 / 79 / 58
Watch LLY NYSE · mega-cap peptide leader	Fundamental watch. No day setup. Swing after price stabilization; long term on valuation/pipeline evidence.	Retatrutide Phase 3 program is advanced; Friday −0.88% to $1,244.40. Counter: expectations, GI/safety, supply, reimbursement and competition.	Confirm above $1,255; invalidate below $1,220. Regulatory, manufacturing and valuation risk.	77 / 72 / 59
Watch AMLX Nasdaq · small/mid-cap binary biotech	Post-financing base watch. Day/swing only after base; long-term speculative pending NDA path.	Prior company-reported Phase 3 LUCIDITY result supports avexitide; no new morning catalyst verified. Counter: filing, review, label, manufacturing and dilution.	Require a fresh base and volume confirmation; do not reuse stale levels. Binary gaps, cash runway and competition. company news	80 / 92 / 55
Watch MRVL Nasdaq · high-beta AI/networking	Earnings watch only. Day: Aug. 27 reaction; swing/long term after guidance.	Nasdaq lists Aug. 27 after-hours results with $0.65 EPS consensus from 8 estimates. Counter: consensus uncertainty, customer concentration and earnings gap.	No pre-event level call. Confirm guidance and post-gap hold. Valuation, custom silicon, networking cycle and rates.	61 / 88 / 57

C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, not outcome probability.

Changes versus the 2026-08-23 report

Regime worsened: neutral/cautious becomes cautious/risk-off lean as NQ futures fall 0.78% and major Asian indices decline.
Material data correction: Sunday's report called Aug. 20 CNBC single-stock observations “Friday.” Direct Nasdaq summaries now show the actual Aug. 21 closes. ANET was −2.60%, not +2.67%; AVGO was −1.20%, not +1.21%; NVDA was +0.99%, not −0.98%; quantum names fell 7%–10% rather than rising. All idea levels derived from the mislabeled observations are withdrawn.
Idea rotation: AVGO moves from conditional long to watch. VRT becomes the top confirmation-only AI idea after verified Friday relative strength. VKTX enters as a strictly speculative small-cap setup; quantum remains avoid-chase.
Live confirmation: weekend policy risk now has tradable indications: gold firmer, oil cheaper, yields lower and equity futures softer. The cross-asset signal is cautious but not a uniform panic.

Important catalysts: next 7–30 days

Aug. 24 · U.S. open
Test whether NQ underperformance, Asian weakness, Iran sanctions and tariff headlines survive the cash open. Opening breadth and 10Y direction are the confirmation tools. NQ

Aug. 26 · 14:30 CEST — GDP second estimate + July income/outlays
Officially scheduled simultaneous growth and PCE information. BEA

Aug. 26 · after U.S. close — NVIDIA FY27 Q2
Nasdaq lists NVDA, CRWD, CRM and SNPS after hours. Watch revenue, guide, gross margin, supply, financing, export controls and data-center read-through. Nasdaq

Aug. 27 · after U.S. close — Marvell
Networking/custom-silicon confirmation; Nasdaq consensus $0.65 from 8 estimates is not company guidance. calendar

Aug. 28 · labor benchmark item — recheck required
BLS schedule returned HTTP 403 again. Date is carried from the prior report and must not be traded without primary re-verification. BLS

Sep. 2 · Broadcom expected earnings
Custom silicon, networking, customer concentration and AI capex. Company IR was blocked this run; treat date as expected pending recheck. Broadcom IR

Sep. 3–4 · U.S. trade and employment
Trade is on the BEA schedule; payrolls are the principal rate-sensitive catalyst. BEA · BLS

Sep. 8 · announced Canadian retaliatory-tariff start
Scope and negotiations may change first. CNBC

Sep. 15–16 · FOMC + projections
Official calendar. Federal Reserve

Bottom line by horizon

Day trade

Bias: defensive until the first 30–60 minutes. Prefer VRT only above $268.20 with breadth; VKTX only above $34.98. Avoid blind quantum/NVDA shorts.

Biggest risk: a headline reversal or opening squeeze. Invalidation: NQ recovers flat, 10Y stays below 4.70% and market breadth turns decisively positive.

1–4 week swing

Bias: keep size light until Wednesday's macro/NVIDIA sequence. Post-event confirmation is superior to prediction.

Biggest risk: yields and AI guidance reprice together. Invalidation: S&P holds above 7,700 with improving breadth and a sustainably lower 10Y; below 7,660 with rising yields worsens the setup.

3–12+ month investment

Bias: prefer profitable, cash-generative AI infrastructure; demand trial/regulatory evidence for biotech and commercial economics for quantum. Use risk-budgeted speculative sleeves.

Biggest risk: peak expectations under high discount rates. Invalidation: durable FCF acceleration, lower long yields or material clinical/commercial de-risking.

Data quality & methodology

Timestamp/session: generated Monday 08:35:39 CEST. CNBC REST quotes were observed around 08:23–08:34 CEST; cash indices are Aug. 21 closes. Asian observations were late-session, not all official final closes. Europe had not opened at the nominal 08:30 report time, so Friday closes are shown.
Successful research: CNBC quote API/world page; Nasdaq quote summaries and earnings API; SEC company-submission JSON; ClinicalTrials.gov API; BEA and Federal Reserve schedules; Google News RSS carrying current market reports; prior published report audit.
Cross-check/correction: Nasdaq's Aug. 21 “Previous Close” fields exposed that CNBC single-stock endpoints were returning Aug. 20 observations. Today's thematic closes use Nasdaq, and the error is disclosed rather than silently overwritten. Dashboard index closes independently match the prior report.
Failures and alternatives: Yahoo chart endpoint returned HTTP 429; Stooq URLs returned HTTP 404; MarketWatch/CNBC web extraction failed for service-credit limits. Market data was therefore retrieved through CNBC's direct quote API and Nasdaq's API. FRED timed out for four series; live yields came from CNBC/Tradeweb. These fields are not declared unavailable because alternatives succeeded.
Primary company access: NVIDIA IR pages returned HTTP 403; IonQ/Lilly IR host lookups failed from this environment. SEC and Nasdaq provided primary/regulatory and calendar alternatives; ClinicalTrials.gov provided trial status. BLS alone remains unverified after direct HTTP 403; its carried catalyst is explicitly labeled.
Scoring: Confidence is evidence quality, never guaranteed probability. Risk rises with valuation, event gaps, liquidity, leverage, dilution and binary exposure. Opportunity balances asymmetry, evidence and timing. Levels are paper-tracking triggers, not orders.

Aman's Global Market Intelligence — 2026-08-24